IDEAYA Biosciences Inc (NASDAQ:IDYA), a United States-based oncology-focused precision medicine company, has named Garret Hampton, PhD as its new director, it was reported on Tuesday.

Dr Hampton has over 25 years of industry experience. Presently, he serves as senior vice president, Clinical Genomics at Illumina. He has also held the position of the global head of Oncology Biomarker Development and Companion Diagnostics at Genentech / Roche and chair of the Roche / Foundation Medicine Joint R&D Committee.

Tim Shannon, MD, chairman of IDEAYA's board of directors, said, 'Garret brings deep industry experience from translational research, biomarker discovery and validation to approved companion diagnostics, and this wealth of knowledge will be invaluable to IDEAYA as it advances its broad pipeline of Synthetic Lethality programs into the clinic, each with a molecularly-defined biomarker hypothesis.'